MiR-130b-3p promotes colorectal cancer progression by targeting CHD9-Reference-Cited by-同舟云学术

MiR-130b-3p promotes colorectal cancer progression by targeting CHD9

Published:2022-01-31 Issue:6 Volume:21 Page:585-601
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Song Dan¹²,Zhang Qian¹,Zhang Hao¹,Zhan Liangliang¹,Sun Xinchen²

Affiliation:

1. Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu, China

2. Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China

Funder

Nanjing Science and Technology Development Project

Publisher

Informa UK Limited

Subject

Cell Biology,Developmental Biology,Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384101.2022.2029240

Reference37 articles.

1. Formas hereditarias de cáncer colorrectal

2. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

3. Global cancer statistics, 2012

4. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

5. Advances in epigenetic biomarker research in colorectal cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening;Alimentary Pharmacology & Therapeutics;2024-03-27

2. miR-130b regulates B cell proliferation via CYLD-mediated NF-κB signaling;Experimental Cell Research;2024-01

3. Human milk miRNAs associate to maternal dietary nutrients, milk microbiota, infant gut microbiota and growth;Clinical Nutrition;2023-12

4. Mutual Regulation of ncRNAs and Chromatin Remodeling Complexes in Normal and Pathological Conditions;International Journal of Molecular Sciences;2023-04-25

5. Endothelin-3 is epigenetically silenced in endometrioid endometrial cancer;Journal of Cancer Research and Clinical Oncology;2022-12-21